Emerging agents for treatment of the relapsed/refractory multiple myeloma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤

ABSTRACT

Relapse/refractory multiple myeloma must be the main tough for the current clinical therapy,thus at the 56th American Society of Hematology annual meeting the latest treatment studies for the disease in 2014 were described in detail,including the joint application of drugs,the new drug clinical research,the safety and efficacy that could be inspiring.This chapter shows the mechanism of these new drug action,as well as the methods and side effects.